Advances in Therapeutic Contact Lenses for the Management of Different Ocular Conditions.
bioavailability
composite
contact lens
drug delivery
gas-permeable
hydrogel
Journal
Journal of personalized medicine
ISSN: 2075-4426
Titre abrégé: J Pers Med
Pays: Switzerland
ID NLM: 101602269
Informations de publication
Date de publication:
03 Nov 2023
03 Nov 2023
Historique:
received:
28
09
2023
revised:
21
10
2023
accepted:
23
10
2023
medline:
25
11
2023
pubmed:
25
11
2023
entrez:
25
11
2023
Statut:
epublish
Résumé
In the advent of an increasingly aging population and due to the popularity of electronic devices, ocular conditions have become more prevalent. In the world of medicine, accomplishing eye medication administration has always been a difficult task. Despite the fact that there are many commercial eye drops, most of them have important limitations, due to quick clearance mechanisms and ocular barrers. One solution with tremendous potential is the contact lens used as a medication delivery vehicle to bypass this constraint. Therapeutic contact lenses for ocular medication delivery have attracted a lot of attention because they have the potential to improve ocular bioavailability and patient compliance, both with minimal side effects. However, it is essential not to compromise essential features such as water content, optical transparency, and modulus to attain positive in vitro and in vivo outcomes with respect to a sustained drug delivery profile from impregnated contact lenses. Aside from difficulties like drug stability and burst release, the changing of lens physico-chemical features caused by therapeutic or non-therapeutic components can limit the commercialization potential of pharmaceutical-loaded lenses. Research has progressed towards bioinspired techniques and smart materials, to improve the efficacy of drug-eluting contact lenses. The bioinspired method uses polymeric materials, and a specialized molecule-recognition technique called molecular imprinting or a stimuli-responsive system to improve biocompatibility and support the drug delivery efficacy of drug-eluting contact lenses. This review encompasses strategies of material design, lens manufacturing and drug impregnation under the current auspices of ophthalmic therapies and projects an outlook onto future opportunities in the field of eye condition management by means of an active principle-eluting contact lens.
Identifiants
pubmed: 38003886
pii: jpm13111571
doi: 10.3390/jpm13111571
pmc: PMC10672201
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
Invest Ophthalmol Vis Sci. 2013 Apr 09;54(4):2551-61
pubmed: 23462746
Cornea. 2020 Feb;39(2):263-270
pubmed: 31498247
Optom Vis Sci. 2012 Aug;89(8):1140-9
pubmed: 22773177
Macromol Biosci. 2005 Aug 12;5(8):728-33
pubmed: 16082622
Pharmaceutics. 2023 May 24;15(6):
pubmed: 37376037
J Ocul Pharmacol Ther. 2022 Jul-Aug;38(6):396-403
pubmed: 35049374
Carbohydr Polym. 2013 Nov 6;98(2):1343-52
pubmed: 24053812
Colloids Surf B Biointerfaces. 2017 Sep 1;157:72-82
pubmed: 28577503
Arch Soc Esp Oftalmol (Engl Ed). 2020 Jan;95(1):24-33
pubmed: 31420118
Eur Cell Mater. 2017 Jan 30;33:59-75
pubmed: 28138955
Clin Exp Optom. 2023 May;106(4):349-350
pubmed: 37121668
Opt Express. 2014 Apr 7;22(7):8035-40
pubmed: 24718178
Materials (Basel). 2018 Jul 01;11(7):
pubmed: 29966397
Eur J Pharm Biopharm. 2015 Aug;94:312-21
pubmed: 26071799
Adv Exp Med Biol. 2018;1078:155-160
pubmed: 30357623
Biosens Bioelectron. 2011 Mar 15;26(7):3290-6
pubmed: 21257302
Cochrane Database Syst Rev. 2015 Mar 24;(3):CD010621
pubmed: 25803325
Sensors (Basel). 2019 May 03;19(9):
pubmed: 31058810
Polymers (Basel). 2022 Apr 20;14(9):
pubmed: 35566843
Clin Exp Optom. 2017 Sep;100(5):529-536
pubmed: 28868619
Asia Pac J Ophthalmol (Phila). 2020 Dec;9(6):524-532
pubmed: 33181548
Invest Ophthalmol Vis Sci. 2015 Oct;56(11):6740-6
pubmed: 26567785
Cornea. 2016 Mar;35(3):417-28
pubmed: 26751990
Molecules. 2021 Sep 14;26(18):
pubmed: 34577045
J Control Release. 2004 Sep 30;99(2):241-58
pubmed: 15380634
J Clin Med. 2022 Feb 18;11(4):
pubmed: 35207362
Biomaterials. 2013 Apr;34(11):2814-21
pubmed: 23337326
J Biomater Sci Polym Ed. 2014;25(17):1907-19
pubmed: 25226305
Int J Biol Macromol. 2020 Oct 15;161:550-560
pubmed: 32534089
Drug Deliv. 2016 Oct;23(8):3017-3026
pubmed: 26821766
Front Med (Lausanne). 2022 Apr 04;9:858784
pubmed: 35445050
Materials (Basel). 2019 Jan 14;12(2):
pubmed: 30646633
Adv Drug Deliv Rev. 2023 May;196:114817
pubmed: 37004938
Korean J Ophthalmol. 2010 Aug;24(4):201-6
pubmed: 20714382
Ophthalmic Physiol Opt. 2004 Nov;24(6):551-61
pubmed: 15491483
J Biol Eng. 2015 Mar 01;9:4
pubmed: 25866560
Clin Ophthalmol. 2020 Oct 23;14:3457-3464
pubmed: 33122881
Acta Biomater. 2010 Oct;6(10):3919-26
pubmed: 20417319
J Ophthalmol. 2012;2012:406850
pubmed: 22288005
Microsyst Nanoeng. 2018 Jul 16;4:18
pubmed: 31057906
Pharmaceutics. 2020 Dec 28;13(1):
pubmed: 33379411
RSC Adv. 2020 Oct 6;10(60):36751-36777
pubmed: 35517957
Pharmaceutics. 2016 Apr 20;8(2):
pubmed: 27104555
Phys Biol. 2006 Feb 02;3(1):S40-53
pubmed: 16582464
Int J Pharm. 2023 May 10;638:122740
pubmed: 36804524
Sci Adv. 2021 Mar 31;7(14):
pubmed: 33789904
Adv Colloid Interface Sci. 2016 Jul;233:139-154
pubmed: 26318359
Polymers (Basel). 2021 Mar 30;13(7):
pubmed: 33808363
ACS Biomater Sci Eng. 2021 Feb 8;7(2):794-803
pubmed: 33464813
Molecules. 2023 Sep 11;28(18):
pubmed: 37764338
Int J Pharm. 2020 May 15;581:119279
pubmed: 32240806
Expert Opin Drug Deliv. 2013 Nov;10(11):1483-96
pubmed: 23875917
Polymers (Basel). 2020 Sep 04;12(9):
pubmed: 32899893
Acta Biomater. 2011 Mar;7(3):1019-30
pubmed: 20934541
Am J Ophthalmol. 2010 Oct;150(4):588; author reply 588-9
pubmed: 20863921
Polymers (Basel). 2019 May 31;11(6):
pubmed: 31159172
Microb Biotechnol. 2022 May;15(5):1422-1433
pubmed: 34773386
Expert Opin Ther Pat. 2015;25(10):1117-29
pubmed: 26143943
Lab Chip. 2020 May 19;20(10):1740-1750
pubmed: 32347844
Int J Pharm. 2015 Jun 20;487(1-2):260-9
pubmed: 25891253
Gels. 2019 Jul 08;5(3):
pubmed: 31288470
Nat Commun. 2017 Apr 27;8:14997
pubmed: 28447604
Biochim Biophys Acta Biomembr. 2022 Nov 1;1864(11):184025
pubmed: 35944665
Bioengineering (Basel). 2019 Oct 09;6(4):
pubmed: 31600967
Ther Adv Ophthalmol. 2021 Jun 24;13:25158414211012796
pubmed: 34263132
Invest Ophthalmol Vis Sci. 2010 Jan;51(1):129-38
pubmed: 19643975
Curr Eye Res. 2019 May;44(5):486-496
pubmed: 30580651
Adv Drug Deliv Rev. 2017 Dec 1;122:31-64
pubmed: 28392306
Polymers (Basel). 2023 Jul 26;15(15):
pubmed: 37571071
J Control Release. 2003 Oct 30;92(3):259-64
pubmed: 14568407
Exp Eye Res. 1998 Jan;66(1):97-103
pubmed: 9533835
J Control Release. 2018 Jul 10;281:97-118
pubmed: 29782944
Eur J Pharm Biopharm. 2021 Apr;161:80-99
pubmed: 33607239
Med Eng Phys. 2014 Sep;36(9):1134-9
pubmed: 25034639
Invest Ophthalmol Vis Sci. 2004 Jul;45(7):2342-7
pubmed: 15223815